Meny

Javascript is not activated in your browser. This website needs javascript activated to work properly.
Du är här

Are European patents obstacles to Swedish cancer research?

Redaktör:
  • Susanne Lundin (professor)
  • Lynn Åkesson (professor)
Publiceringsår: 2002
Språk: Engelska
Sidor: 52-71
Publikation/Tidskrift/Serie: Gene technology and economy
Dokumenttyp: Del av eller Kapitel i bok
Förlag: Nordic Academic Press

Sammanfattning

Professor Håkan Olsson, Lund has addressed the problems caused by patenting in the field of biotechnology. His article was triggered by patent protection acquired by the American company Myriad Genetics. According to HO, Myriad requires that analyses of blood to trace the occurrence of these genes should be carried out in the company’s American laboratories, at a significant cost. Profit is infringing on the freedom of academic research and HO therefore asks:
• Is it reasonable to patent “inventions” in gene technology?
• Can patent protection be allowed to impede urgent, serious and non-commercial research?
• Can patent protection be circumvented by coercive measures?
• Should patentees be able to monopolize analytical work in medical care?
In this article I examine the system from a legal perspective. Are there solutions to the problems encountered by a researching physician, or must the rules be changed?

Disputation

Nyckelord

  • Law and Political Science
  • civilrätt: immaterialrätt
  • private law: intellectual property law
  • biotechnology
  • patenting
  • research exemption.

Övriga

Published
Yes
For a Swedish version see ”Hindrar europeiska genpatent svensk cancerforskning?
  • ISBN: 9189116259

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen